We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
- Recent CRL Stock Price: $245.40
- Yearly Gain for CRL stock: -2.44%
- Market Cap for CRL stock: $12.59B
- P/E Ratio for CRL stock: 26.59
Will CRL's stock price go up? Is there an accurate CRL stock forecast available?
TipRanks.com reports that Charles River Laboratories International, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $267.00. The target pricing ranges from a high CRL forecast of $290 down to a low forecast of $250. Charles River Laboratories International, Inc. (CRL)’s last closing stock price was $245.40 which would put the average price target at 8.80% upside.
In addition, TradingView issued a rating for CRL stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CRL stock.
Other analysts covering CRL include:
- Eric Coldwell of Robert W. Baird issued a Buy rating with the price target of $268 on 20 hours ago
- Charles Rhyee of TD Cowen issued a Hold rating with the price target of $260 on 20 hours ago
- Patrick B Donnelly of Citi issued a Hold rating with the price target of $250 on 20 hours ago
If you are wondering if CRL is a good stock to buy, here are 3rd party ratings for CRL stock:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (97 out of 250)
What is the sentiment on the street regarding Charles River Laboratories International, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for CRL stock: Bullish
- Blogger Consensus for CRL stock: {Blogger Consensus}
- Media Buzz for CRL stock: Strong Buy
- Insider Signal for CRL stock: Balanced
- Investor Sentiment for CRL stock: Positive
- Hedge Fund signal for CRL stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on CRL stock including scouring the social networks like CRL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CRL stock chart >>
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
- Recent BIIB Stock Price: $223.35
- Yearly Gain for BIIB stock: -19.94%
- Market Cap for BIIB stock: $32.36B
- P/E Ratio for BIIB stock: 28.02
Will BIIB's stock price go up? Is there an accurate BIIB stock forecast available?
TipRanks.com reports that Biogen Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $275.20. The target pricing ranges from a high BIIB forecast of $325 down to a low forecast of $230. Biogen Inc. (BIIB)’s last closing stock price was $223.35 which would put the average price target at 23.21% upside.
In addition, TradingView issued a rating for BIIB stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB stock.
Other analysts covering BIIB include:
- Elmar Kraus of DZ BANK AG issued a Hold rating with the price target of $236 on 20 hours ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $325 on 1 day ago
- Ami Fadia of Needham issued a Buy rating with the price target of $300 on 1 day ago
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $285 on 1 day ago
If you are wondering if BIIB is a good stock to buy, here are 3rd party ratings for BIIB stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 35% (87 out of 250)
What is the sentiment on the street regarding Biogen Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for BIIB stock: Bullish
- Blogger Consensus for BIIB stock: {Blogger Consensus}
- Media Buzz for BIIB stock: Buy
- Insider Signal for BIIB stock: Balanced
- Investor Sentiment for BIIB stock: Negative
- Hedge Fund signal for BIIB stock: Risk Not Mentioned
The stock market is extremely volatile, and you need to do your own research on BIIB stock including scouring the social networks like BIIB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BIIB stock chart >>
Summary: IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. I
- Recent IQV Stock Price: $241.47
- Yearly Gain for IQV stock: 6.36%
- Market Cap for IQV stock: $44.07B
- P/E Ratio for IQV stock: 40.45
Will IQV's stock price go up? Is there an accurate IQV stock forecast available?
TipRanks.com reports that IQVIA Holdings Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $277.75. The target pricing ranges from a high IQV forecast of $300 down to a low forecast of $251. IQVIA Holdings Inc. (IQV)’s last closing stock price was $241.47 which would put the average price target at 15.02% upside.
In addition, TradingView issued a rating for IQV stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IQV stock.
Other analysts covering IQV include:
- Dan Leonard of UBS issued a Buy rating with the price target of $300 on 20 hours ago
- Eric Coldwell of Robert W. Baird issued a Hold rating with the price target of $251 on 20 hours ago
- Charles Rhyee of TD Cowen issued a Buy rating with the price target of $270 on 20 hours ago
- Justin Bowers of Deutsche Bank issued a Buy rating with the price target of $290 on 20 hours ago
If you are wondering if IQV is a good stock to buy, here are 3rd party ratings for IQV stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 41% (103 out of 250)
What is the sentiment on the street regarding IQVIA Holdings Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for IQV stock: Bullish
- Blogger Consensus for IQV stock: {Blogger Consensus}
- Media Buzz for IQV stock: Strong Buy
- Insider Signal for IQV stock: Buying
- Investor Sentiment for IQV stock: Positive
- Hedge Fund signal for IQV stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on IQV stock including scouring the social networks like IQV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IQV stock chart >>
Summary: SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
- Recent SAGE Stock Price: $25.41
- Yearly Gain for SAGE stock: -43.67%
- Market Cap for SAGE stock: $1.53B
- P/E Ratio for SAGE stock: -2.31
Will SAGE's stock price go up? Is there an accurate SAGE stock forecast available?
TipRanks.com reports that Sage Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $28.25. The target pricing ranges from a high SAGE forecast of $34 down to a low forecast of $25. Sage Therapeutics, Inc. (SAGE)’s last closing stock price was $25.41 which would put the average price target at 11.18% upside.
In addition, TradingView issued a rating for SAGE stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SAGE stock.
Other analysts covering SAGE include:
- George Farmer of Scotiabank issued a Buy rating with the price target of $34 on 20 hours ago
- Douglas Tsao of H.C. Wainwright issued a Hold rating with the price target of $28 on 20 hours ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $26 on 1 day ago
If you are wondering if SAGE is a good stock to buy, here are 3rd party ratings for SAGE stock:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 39% (97 out of 250)
What is the sentiment on the street regarding Sage Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SAGE stock: Bearish
- Blogger Consensus for SAGE stock: {Blogger Consensus}
- Media Buzz for SAGE stock: Sell
- Insider Signal for SAGE stock: Buying
- Investor Sentiment for SAGE stock: Negative
- Hedge Fund signal for SAGE stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on SAGE stock including scouring the social networks like SAGE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SAGE stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================